AU2003215673A1 - Tenascin-w compositions and uses thereof - Google Patents

Tenascin-w compositions and uses thereof Download PDF

Info

Publication number
AU2003215673A1
AU2003215673A1 AU2003215673A AU2003215673A AU2003215673A1 AU 2003215673 A1 AU2003215673 A1 AU 2003215673A1 AU 2003215673 A AU2003215673 A AU 2003215673A AU 2003215673 A AU2003215673 A AU 2003215673A AU 2003215673 A1 AU2003215673 A1 AU 2003215673A1
Authority
AU
Australia
Prior art keywords
tenascin
seq
amino acid
cell
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003215673A
Other languages
English (en)
Inventor
Ruth Chiquet-Ehrismann
Arnaud Scherberich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute for Biomedical Research
Original Assignee
Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute for Biomedical Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute for Biomedical Research filed Critical Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute for Biomedical Research
Publication of AU2003215673A1 publication Critical patent/AU2003215673A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU2003215673A 2002-03-27 2003-03-26 Tenascin-w compositions and uses thereof Abandoned AU2003215673A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0207224.7 2002-03-27
GBGB0207224.7A GB0207224D0 (en) 2002-03-27 2002-03-27 Tenascin-W compositions and uses thereof
PCT/EP2003/003150 WO2003080663A2 (en) 2002-03-27 2003-03-26 Tenascin-w compositions and uses thereof

Publications (1)

Publication Number Publication Date
AU2003215673A1 true AU2003215673A1 (en) 2003-10-08

Family

ID=9933815

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003215673A Abandoned AU2003215673A1 (en) 2002-03-27 2003-03-26 Tenascin-w compositions and uses thereof

Country Status (7)

Country Link
US (2) US7683159B2 (enExample)
EP (1) EP1490400A2 (enExample)
JP (1) JP4469180B2 (enExample)
AU (1) AU2003215673A1 (enExample)
CA (1) CA2480050A1 (enExample)
GB (1) GB0207224D0 (enExample)
WO (1) WO2003080663A2 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL160507A0 (en) * 2001-08-24 2004-07-25 Advanced Cell Tech Inc Screening assays for identifying differentiation-inducing agents and production of differentiated cells for cell therapy
WO2009053354A1 (en) * 2007-10-22 2009-04-30 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Use of tenascin-w as a biomarker for colon cancer
EP2241323A1 (en) * 2009-04-14 2010-10-20 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Tenascin-W and brain cancers
GB201413357D0 (en) * 2014-07-28 2014-09-10 Philogen Spa Antibodies for treatment and diagnosis
CA3068688A1 (en) * 2017-06-30 2019-01-03 National Institutes Of Biomedical Innovation, Health And Nutrition Biomarker for detecting colorectal cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992004464A2 (en) 1990-09-05 1992-03-19 The Wistar Institute Monoclonal antibodies against tenascin
WO1994021293A1 (en) 1993-03-19 1994-09-29 Duke University Method of treatment of tumors with an antibody binding to tenascin
US6124260A (en) 1998-09-30 2000-09-26 Cedars-Sinai Medical Center Inhibition of smooth muscle cell migration by Tenascin-C peptides
AU2001238585A1 (en) * 2000-02-24 2001-09-03 Human Genome Sciences, Inc. Human polynucleotides, polypeptides, and antibodies
US20030022255A1 (en) 2000-12-22 2003-01-30 Morris David W. Novel compositions and methods for breast cancer
US7892730B2 (en) * 2000-12-22 2011-02-22 Sagres Discovery, Inc. Compositions and methods for cancer

Also Published As

Publication number Publication date
CA2480050A1 (en) 2003-10-02
US7683159B2 (en) 2010-03-23
JP4469180B2 (ja) 2010-05-26
WO2003080663A2 (en) 2003-10-02
JP2006504397A (ja) 2006-02-09
US20050202430A1 (en) 2005-09-15
WO2003080663A3 (en) 2004-04-01
GB0207224D0 (en) 2002-05-08
US20100173314A1 (en) 2010-07-08
EP1490400A2 (en) 2004-12-29

Similar Documents

Publication Publication Date Title
CN101389958B (zh) 使用轴突导向因子netrin-1的活性筛选抗癌化合物的方法
JP3275024B2 (ja) 血管内皮増殖因子−ｂ
KR101560843B1 (ko) 페리오스틴의 Ｅｘｏｎ-17 부위에 의해 코드되는 펩티드에 대한 항체를 함유하는 암 치료제
JP2011501741A (ja) がんの診断および治療のためのｔａｚ／ｗｗｔｒ１
US20120058572A1 (en) Antibody against periostin, and a pharmaceutical composition comprising it for preventing or treating a disease in which periostin is involved
EP1978034B1 (en) Anti-periostin antibody and pharmaceutical composition containing the same for preventing or treating periostin-related disease
US20040259781A1 (en) Anti-tumour agents and methods of identifying anti-tumour agents
US20100173314A1 (en) Diagnostic methods using tenascin-w compositions
US20210079099A1 (en) Antibody against alpha-11 integrin and its use
AU2011249750B2 (en) Antagonists of Sema3E/PlexinD1 interaction as anti-cancer agents
EP1695078A2 (en) Metadherin polypeptides, encoding nucleic acids and methods of use
KR101008314B1 (ko) Ｃｄ９이 과발현된 고형암의 항암제 개발을 위한표적단백질로서의 ｃｄ９의 용도
JPH10502252A (ja) Ｄｐ−１及びその他のｄｐタンパク質の阻害剤のアッセイ
Schaefer et al. Expression of the helix–loop–helix protein id1 in keratinocytes is upregulated by loss of cell–matrix contact
JP2006504397A5 (enExample)
KR20140144934A (ko) Ｃｔｈｒｃ１의 발현 및 활성 억제제를 유효성분으로 포함하는 췌장암 치료 및 전이억제용 조성물
KR102268041B1 (ko) 구강암의 예후 예측용 조성물
Meghnani RAGE (Receptor for Advanced Glycation End Products) in melanoma progression
HK1180002B (en) Antagonists of sema3e/plexind1 interaction as anti-cancer agents
WO2005030805A1 (ja) 新規タンパク質複合体およびその用途
JP2005120082A (ja) 新規タンパク質複合体およびその用途

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted